Connection

Lee Chao to Humans

This is a "connection" page, showing publications Lee Chao has written about Humans.
Connection Strength

0.680
  1. Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2018; 2018:4138560.
    View in: PubMed
    Score: 0.024
  2. Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. Oxid Med Cell Longev. 2017; 2017:5262958.
    View in: PubMed
    Score: 0.023
  3. Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem. 2017 11 27; 398(12):1309-1317.
    View in: PubMed
    Score: 0.023
  4. Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression. Oxid Med Cell Longev. 2017; 2017:5025610.
    View in: PubMed
    Score: 0.022
  5. Kallistatin suppresses cancer development by multi-factorial actions. Crit Rev Oncol Hematol. 2017 May; 113:71-78.
    View in: PubMed
    Score: 0.022
  6. Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension. 2016 09; 68(3):533-41.
    View in: PubMed
    Score: 0.021
  7. Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res. 2014; 69:37-57.
    View in: PubMed
    Score: 0.017
  8. Tissue kallikrein is related to the severity of coronary artery disease. Clin Chim Acta. 2013 Aug 23; 423:90-8.
    View in: PubMed
    Score: 0.017
  9. Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
    View in: PubMed
    Score: 0.016
  10. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 2012 Aug; 23(8):859-70.
    View in: PubMed
    Score: 0.015
  11. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010 Apr; 391(4):345-55.
    View in: PubMed
    Score: 0.013
  12. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
    View in: PubMed
    Score: 0.011
  13. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006 Jun; 387(6):665-75.
    View in: PubMed
    Score: 0.010
  14. Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
    View in: PubMed
    Score: 0.010
  15. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005 May; 54(5):1573-80.
    View in: PubMed
    Score: 0.010
  16. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005 May; 90(3):291-8.
    View in: PubMed
    Score: 0.009
  17. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
    View in: PubMed
    Score: 0.009
  18. Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty. Regul Pept. 2003 Apr 15; 112(1-3):115-20.
    View in: PubMed
    Score: 0.008
  19. Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats. Am J Physiol Regul Integr Comp Physiol. 2003 Apr; 284(4):R1031-6.
    View in: PubMed
    Score: 0.008
  20. Adenovirus-mediated gene transfer for cardiovascular and renal diseases. Methods Enzymol. 2002; 346:247-63.
    View in: PubMed
    Score: 0.008
  21. Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides. 2001 Nov; 22(11):1731-7.
    View in: PubMed
    Score: 0.007
  22. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2001 Jun; 280(6):F964-71.
    View in: PubMed
    Score: 0.007
  23. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem. 2001 Jan; 382(1):15-21.
    View in: PubMed
    Score: 0.007
  24. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000 Dec; 36(6):995-1001.
    View in: PubMed
    Score: 0.007
  25. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999 Oct 15; 44(1-2):57-65.
    View in: PubMed
    Score: 0.006
  26. Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 Jun; 14(6):1376-84.
    View in: PubMed
    Score: 0.006
  27. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999 Jan; 33(1 Pt 2):219-24.
    View in: PubMed
    Score: 0.006
  28. Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice. J Am Heart Assoc. 2018 11 06; 7(21):e009562.
    View in: PubMed
    Score: 0.006
  29. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int. 1998 Oct; 54(4):1250-60.
    View in: PubMed
    Score: 0.006
  30. Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway. J Cell Mol Med. 2018 09; 22(9):4387-4398.
    View in: PubMed
    Score: 0.006
  31. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther. 1998 Jan 01; 9(1):21-31.
    View in: PubMed
    Score: 0.006
  32. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res. 1997 Dec; 20(4):269-77.
    View in: PubMed
    Score: 0.006
  33. New experimental evidence for a role of tissue kallikrein in hypertension. Nephrol Dial Transplant. 1997 Aug; 12(8):1569-74.
    View in: PubMed
    Score: 0.006
  34. Kallistatin is a potent new vasodilator. J Clin Invest. 1997 Jul 01; 100(1):11-7.
    View in: PubMed
    Score: 0.006
  35. DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene. Hum Genet. 1997 Jun; 99(6):727-34.
    View in: PubMed
    Score: 0.006
  36. Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology. 1997 Jun; 36(2-3):229-36.
    View in: PubMed
    Score: 0.006
  37. Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol. 1997 Jun; 75(6):750-6.
    View in: PubMed
    Score: 0.006
  38. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res. 1997 Jun; 35(6):517-22.
    View in: PubMed
    Score: 0.006
  39. Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS One. 2017; 12(5):e0178387.
    View in: PubMed
    Score: 0.005
  40. Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway. Aging Cell. 2017 08; 16(4):837-846.
    View in: PubMed
    Score: 0.005
  41. Expression and localization of human kallistatin in rat submandibular gland after intracapsular gene injection. Biochem Biophys Res Commun. 1997 Feb 13; 231(2):494-8.
    View in: PubMed
    Score: 0.005
  42. High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens. 1996 Nov; 18(8):975-93.
    View in: PubMed
    Score: 0.005
  43. Identification and characterization of two promoters of rat kallikrein-binding protein gene. Biochim Biophys Acta. 1996 Jul 17; 1307(3):285-93.
    View in: PubMed
    Score: 0.005
  44. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med. 1996 Jun; 127(6):612-20.
    View in: PubMed
    Score: 0.005
  45. Tissue kallikrein inhibitors in mammals. Immunopharmacology. 1996 May; 32(1-3):67-72.
    View in: PubMed
    Score: 0.005
  46. High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. Immunopharmacology. 1996 May; 32(1-3):105-7.
    View in: PubMed
    Score: 0.005
  47. Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension. 1996 Mar; 27(3 Pt 2):491-4.
    View in: PubMed
    Score: 0.005
  48. Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp Cell Res. 2016 Jan 15; 340(2):305-14.
    View in: PubMed
    Score: 0.005
  49. Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. Genomics. 1996 Jan 01; 31(1):51-7.
    View in: PubMed
    Score: 0.005
  50. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995 Dec; 26(6 Pt 1):847-53.
    View in: PubMed
    Score: 0.005
  51. Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler. 1995 Dec; 376(12):705-13.
    View in: PubMed
    Score: 0.005
  52. Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015 Jul 22; 5:12463.
    View in: PubMed
    Score: 0.005
  53. Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. Antimicrob Agents Chemother. 2015 Sep; 59(9):5619-30.
    View in: PubMed
    Score: 0.005
  54. Kallistatin inhibits TGF-?-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res. 2015 Sep 10; 337(1):103-10.
    View in: PubMed
    Score: 0.005
  55. Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care. 2015 May 01; 19:200.
    View in: PubMed
    Score: 0.005
  56. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem. 1995 Jan 06; 270(1):451-5.
    View in: PubMed
    Score: 0.005
  57. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 1994 Sep 15; 23(2):362-9.
    View in: PubMed
    Score: 0.005
  58. Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). Genomics. 1994 Sep 15; 23(2):370-8.
    View in: PubMed
    Score: 0.005
  59. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014 Jun; 142(2):216-26.
    View in: PubMed
    Score: 0.004
  60. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993 Nov 15; 268(32):24498-505.
    View in: PubMed
    Score: 0.004
  61. Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. Antimicrob Agents Chemother. 2013 Nov; 57(11):5366-72.
    View in: PubMed
    Score: 0.004
  62. Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
    View in: PubMed
    Score: 0.004
  63. Kallistatin antagonizes Wnt/?-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem. 2013 Jul; 379(1-2):295-301.
    View in: PubMed
    Score: 0.004
  64. Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care. 2013 Feb 08; 17(1):R27.
    View in: PubMed
    Score: 0.004
  65. Comparative studies on P2 specificity of wild-type rat tissue kallikrein, Y99H:W215G mutant and tonin. Agents Actions Suppl. 1992; 38 ( Pt 1):59-65.
    View in: PubMed
    Score: 0.004
  66. Evolution of the kallikrein gene family. Agents Actions Suppl. 1992; 38 ( Pt 1):26-33.
    View in: PubMed
    Score: 0.004
  67. Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem. 2010 Jul; 391(7):803-12.
    View in: PubMed
    Score: 0.003
  68. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 2010 Aug; 56(2):260-7.
    View in: PubMed
    Score: 0.003
  69. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer. 2010 May 31; 10:245.
    View in: PubMed
    Score: 0.003
  70. Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F1033-40.
    View in: PubMed
    Score: 0.003
  71. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 15 Suppl 6:S7-16.
    View in: PubMed
    Score: 0.003
  72. Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem. 2009 Dec 18; 284(51):35471-8.
    View in: PubMed
    Score: 0.003
  73. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2010 Feb 01; 316(3):376-89.
    View in: PubMed
    Score: 0.003
  74. Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 2009 Sep; 297(3):H1040-7.
    View in: PubMed
    Score: 0.003
  75. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther. 2009 Feb; 20(2):147-58.
    View in: PubMed
    Score: 0.003
  76. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1735-43.
    View in: PubMed
    Score: 0.003
  77. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest. 2008 Nov; 88(11):1157-66.
    View in: PubMed
    Score: 0.003
  78. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008 Dec 01; 80(3):354-64.
    View in: PubMed
    Score: 0.003
  79. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
    View in: PubMed
    Score: 0.003
  80. Circulating autoantibodies to mammalian tissue kallikreins. Proc Soc Exp Biol Med. 1988 Mar; 187(3):320-6.
    View in: PubMed
    Score: 0.003
  81. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008 Jan 16; 82(3-4):156-65.
    View in: PubMed
    Score: 0.003
  82. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol. 2007 Nov; 34(11):2171-6.
    View in: PubMed
    Score: 0.003
  83. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
    View in: PubMed
    Score: 0.003
  84. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007 Jan 01; 73(1):130-42.
    View in: PubMed
    Score: 0.003
  85. Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. Am J Physiol Renal Physiol. 2006 Sep; 291(3):F567-77.
    View in: PubMed
    Score: 0.003
  86. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
    View in: PubMed
    Score: 0.003
  87. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
    View in: PubMed
    Score: 0.002
  88. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 2005 Apr; 52(4):1319-24.
    View in: PubMed
    Score: 0.002
  89. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
    View in: PubMed
    Score: 0.002
  90. Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 Jun; 24(6):1104-10.
    View in: PubMed
    Score: 0.002
  91. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov; 42(5):1026-33.
    View in: PubMed
    Score: 0.002
  92. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1479-88.
    View in: PubMed
    Score: 0.002
  93. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
    View in: PubMed
    Score: 0.002
  94. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol. 2003 06; 284(6):C1604-13.
    View in: PubMed
    Score: 0.002
  95. Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation. 2002 Jan 01; 105(1):67-72.
    View in: PubMed
    Score: 0.002
  96. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001 Nov; 159(5):1797-805.
    View in: PubMed
    Score: 0.002
  97. Identification of a major heparin-binding site in kallistatin. J Biol Chem. 2001 Jan 12; 276(2):1276-84.
    View in: PubMed
    Score: 0.002
  98. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem. 2000 Dec 08; 275(49):38457-66.
    View in: PubMed
    Score: 0.002
  99. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther. 2000 Sep 01; 11(13):1817-27.
    View in: PubMed
    Score: 0.002
  100. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
    View in: PubMed
    Score: 0.002
  101. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta. 2000 Jun 15; 1479(1-2):237-46.
    View in: PubMed
    Score: 0.002
  102. Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol. 2000 Mar; 278(3):F484-91.
    View in: PubMed
    Score: 0.002
  103. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
    View in: PubMed
    Score: 0.002
  104. Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology. 1999 Oct 15; 44(1-2):137-43.
    View in: PubMed
    Score: 0.002
  105. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke. 1999 Sep; 30(9):1925-31; discussion 1931-2.
    View in: PubMed
    Score: 0.002
  106. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999 Aug; 34(2):164-70.
    View in: PubMed
    Score: 0.002
  107. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem. 1999 Feb; 47(2):221-8.
    View in: PubMed
    Score: 0.002
  108. Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta. 1998 Nov 08; 1442(2-3):177-85.
    View in: PubMed
    Score: 0.002
  109. Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands. Histochem Cell Biol. 1998 Nov; 110(5):477-84.
    View in: PubMed
    Score: 0.002
  110. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 1998 May; 53(5):1305-13.
    View in: PubMed
    Score: 0.001
  111. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension. 1998 May; 31(5):1104-10.
    View in: PubMed
    Score: 0.001
  112. Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun. 1998 Mar 17; 244(2):449-54.
    View in: PubMed
    Score: 0.001
  113. Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem. 1998 Jan 30; 273(5):2784-91.
    View in: PubMed
    Score: 0.001
  114. Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther. 1997 Oct 10; 8(15):1753-61.
    View in: PubMed
    Score: 0.001
  115. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997 Sep; 30(3 Pt 1):307-13.
    View in: PubMed
    Score: 0.001
  116. Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice. Biochem J. 1997 Jul 01; 325 ( Pt 1):111-6.
    View in: PubMed
    Score: 0.001
  117. Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology. 1997 Jun; 36(2-3):221-7.
    View in: PubMed
    Score: 0.001
  118. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther. 1997 Feb 10; 8(3):341-7.
    View in: PubMed
    Score: 0.001
  119. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension. 1997 Jan; 29(1 Pt 2):488-93.
    View in: PubMed
    Score: 0.001
  120. Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res. 1996 Nov; 15(11):1117-23.
    View in: PubMed
    Score: 0.001
  121. Expression and cellular localization of tissue kallikrein-kinin system in human adrenal gland. Am J Physiol. 1996 Sep; 271(3 Pt 2):F709-16.
    View in: PubMed
    Score: 0.001
  122. Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res. 1996 Jul; 63(1):19-26.
    View in: PubMed
    Score: 0.001
  123. Cellular localization of low-molecular-weight kininogen and bradykinin B2 receptor mRNAs in human kidney. Am J Physiol. 1996 Jun; 270(6 Pt 2):F919-26.
    View in: PubMed
    Score: 0.001
  124. Cellular localization of bradykinin B1 receptor mRNA in the human kidney. Immunopharmacology. 1996 Jun; 33(1-3):151-6.
    View in: PubMed
    Score: 0.001
  125. Structure and chromosomal localization of the human prostasin (PRSS8) gene. Genomics. 1996 Mar 15; 32(3):334-40.
    View in: PubMed
    Score: 0.001
  126. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int. 1995 Sep; 48(3):690-7.
    View in: PubMed
    Score: 0.001
  127. Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem. 1995 Jun 02; 270(22):13483-9.
    View in: PubMed
    Score: 0.001
  128. Molecular cloning, purification and in situ localization of human colon kallikrein. Biochem J. 1995 Apr 15; 307 ( Pt 2):481-6.
    View in: PubMed
    Score: 0.001
  129. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995 Apr; 95(4):1710-6.
    View in: PubMed
    Score: 0.001
  130. Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. Gene. 1994 Nov 18; 149(2):283-8.
    View in: PubMed
    Score: 0.001
  131. Molecular cloning and characterization of a novel kallikrein transcript in colon and its distribution in human tissues. Braz J Med Biol Res. 1994 Aug; 27(8):1829-38.
    View in: PubMed
    Score: 0.001
  132. Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem. 1994 Jul 22; 269(29):18843-8.
    View in: PubMed
    Score: 0.001
  133. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem. 1992 Dec 25; 267(36):25873-80.
    View in: PubMed
    Score: 0.001
  134. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J Lab Clin Med. 1992 May; 119(5):514-21.
    View in: PubMed
    Score: 0.001
  135. Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein. Biochem J. 1990 Apr 01; 267(1):79-84.
    View in: PubMed
    Score: 0.001
  136. Molecular cloning and primary structure of rat alpha 1-antitrypsin. Biochemistry. 1990 Jan 16; 29(2):323-9.
    View in: PubMed
    Score: 0.001
  137. Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization. Adv Exp Med Biol. 1989; 247B:1-8.
    View in: PubMed
    Score: 0.001
  138. Expression of the Thy-1 gene in human T lymphoid cell lines. Immunol Lett. 1988 Oct; 19(2):109-13.
    View in: PubMed
    Score: 0.001
  139. Special antigens on sperm from autoimmune infertile men. Am J Reprod Immunol Microbiol. 1988 May; 17(1):5-13.
    View in: PubMed
    Score: 0.001
  140. Sperm and seminal plasma antigens from autoimmune men induce immunological infertility. Arch Androl. 1987; 19(2):161-75.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.